Oncology
Latest news
826 articles · 20 / page
Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma
A secondary analysis of the CAPTAIN-1st trial reveals that adding camrelizumab to first-line chemotherapy significantly improves five-year overall survival in RM-NPC, with a 37.8% survival rate and notable benefits linked to rapid EBV DNA c
The Precision Gap: Evaluating Sentinel Lymph Node Biopsy in Head and Neck Merkel Cell Carcinoma
This article examines the clinical accuracy of Sentinel Lymph Node Biopsy for head and neck Merkel cell carcinoma, highlighting a significant false-negative rate and identifying risk factors that necessitate more personalized treatment stra
Low-Dose Aspirin and Cancer Mortality in Older Adults: Long-Term ASPREE Results Challenge Previous Paradigms
A 10-year follow-up of the ASPREE trial reveals that low-dose aspirin does not reduce cancer incidence in adults aged 70 and older, but is associated with increased cancer-related mortality, challenging long-held assumptions about aspirin’s
Proton Therapy Redefines the Standard of Care for Nasopharyngeal Carcinoma: Insights from a Landmark Case-Control Study
A comprehensive case-control study published in The Lancet Regional Health – Americas highlights how Intensity-Modulated Proton Therapy (IMPT) significantly reduces toxicities and improves quality of life for nasopharyngeal carcinoma patien
Intensity-Modulated Proton Therapy Reduces Acute Toxicity While Maintaining Oncologic Equivalence in Nasopharyngeal Carcinoma: A Five-Year Case-Control Analysis
A case-control study comparing IMPT and IMRT for nasopharyngeal carcinoma shows that IMPT significantly reduces grade 2+ acute toxicities without compromising long-term survival or local-regional control, suggesting a superior therapeutic i
Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection
A massive 21-country study confirms that mammography screening has significantly shifted breast cancer detection toward earlier stages, contributing to a substantial decline in mortality across Europe, though treatment advances also play a
Activating EGFR L858R Variants Linked to Syndromic Generalized Acanthosis Nigricans and Pulmonary Risk: A New Clinical Entity
This study identifies activating EGFR L858R variants as the genetic basis for a syndrome featuring generalized acanthosis nigricans and lung nodules, highlighting the efficacy of EGFR inhibitors in treating both cutaneous and systemic manif
Histologic Subtype Dictates the Survival Benefit of Guideline-Adherent Lymph Node Dissection in T1N0M0 Lung Adenocarcinoma
A large-scale multicenter study reveals that adherence to lymph node dissection guidelines significantly improves survival in early-stage lung adenocarcinoma patients with high-grade histologic patterns, while offering no significant benefi
Incident Splenomegaly: Defining Clinical Thresholds for Hematologic Cancer and Liver Disease Risk
This large-scale prospective cohort study identifies specific spleen length and volume thresholds that significantly increase the 5-year risk of hematologic malignancies and liver disease, providing a data-driven framework for clinical work
Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD
A multicenter study reveals significant discordance between clinician and patient assessments of skin cGVHD. While both correlate with survival, patient-reported outcomes are uniquely predictive of mortality in sclerotic disease, highlighti
Long-Term Survival vs. Short-Term Quality of Life: Deciding the Fate of Esophageal Cancer Responders
A decision analytical model based on the SANO trial suggests that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy remains superior for maximizing long-term survival and quality-adjusted life-year
Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring
A new study reveals that ‘tumor-informed’ blood tests can detect recurring head and neck cancer months before traditional scans, offering a critical window for intervention in high-risk patients.
Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC
The phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrates that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival and duration of response compared to standard chemotherapy plus pembrolizumab in patients wi
EsoTIME: Precision Survival Prediction Replaces Traditional Staging for Resected Esophageal and Gastroesophageal Junction Cancers
The EsoTIME tool provides a validated, high-accuracy method for predicting 3-year survival in patients with resected esophageal and gastroesophageal junction cancers, utilizing population-based data to improve personalized clinical decision
Interactive Mobile Coaching Improves Long-Term Quality of Life and Symptom Management After Gastrectomy
A randomized controlled trial demonstrates that early interactive human coaching via a mobile app improves long-term quality of life, reduces dyspnea, and eases eating restrictions in postgastrectomy patients, particularly among younger and
Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study
The PHENOMENAL phase 2 study reveals that liposomal irinotecan (nal-IRI) achieves a 22% intracranial objective response rate in patients with HER2-negative breast cancer and brain metastases, addressing a critical unmet need in neuro-oncolo
Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial
The RJBC 1501 Phase III trial demonstrates that adding carboplatin to adjuvant EC-T chemotherapy significantly improves disease-free, distant disease-free, and overall survival in early-stage TNBC patients, despite a manageable increase in
Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma
Recent clinical trials establish dinutuximab beta as a cornerstone of neuroblastoma therapy, demonstrating significant survival benefits when combined with chemotherapy in relapsed cases, while clarifying that adding Interleukin-2 to standa
GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers
Clinical trials evaluate elraglusib, a GSK-3β inhibitor, in salivary gland and pancreatic cancers. While results were mixed, findings highlight the importance of nuclear GSK-3β expression as a biomarker and the need for dose optimization to
Anlotinib Combined with Anthracycline-Ifosfamide Regimen Shows Promising Efficacy in First-line Treatment of Advanced Soft-Tissue Sarcoma
This Phase II trial evaluates first-line anlotinib plus anthracyclines and ifosfamide followed by anlotinib maintenance for advanced soft-tissue sarcoma, showing an objective response rate of 30.8% and a manageable safety profile, suggestin
Browse by specialty
Open language-specific specialty feeds and department pages.